Clincosm LogoSign in Get a demo

Urine Adiponectin Concentration in Prediction of Contrast Induced Nephropathy

Sponsor
Xijing Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT01372891
Collaborator
(none)
400
Enrollment
1
Location
56
Duration (Months)
7.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of contrast induced nephropathy (CIN) in the patients undergoing PCI.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Contrast induced nephropathy (CIN) is a severe complication after percutaneous coronary intervention (PCI). CIN is responsible for approximately genic renal insufficiency and is the third cause of hospital-acquired renal failure and the injury of endothelial of renal tubule is responsible for the CIN. However markers reliably identifying CIN in the patients undergoing PCI are rare. Adiponectin is a 30-kDa adipocyte-derived vasoactive peptide closely linked to components of the metabolic syndrome. Recent study demonstrates that the quantification of urinary adiponectin excretion appears to be an independent indicator of vascular damage potentially identifying an increased risk for vascular events. Therefore, the investigators presume that the adiponectin excretion may predict the incidence of the CIN. The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of CIN in the patients undergoing PCI.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    400 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Urine Total Adiponectin and Its Isoforms Concentration in Prediction of Percutaneous Coronary Interventions Contrast Induced Nephropathy
    Study Start Date :
    Apr 1, 2010
    Anticipated Primary Completion Date :
    Apr 1, 2013
    Anticipated Study Completion Date :
    Dec 1, 2014

    Arms and Interventions

    Arm Intervention/Treatment
    Patients underging PCI

    Outcome Measures

    Primary Outcome Measures

    1. increase in SCr 0.5 mg/dL(44.2 mol/L) from baseline [3 days]

      samples will be collected at 24, 48 and 72 hours after PCI

    Secondary Outcome Measures

    1. a 25% increase in SCr from baseline [3 days]

      samples will be collected at 24, 48 and 72 hours after PCI.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All patients > 18 of age who are undergoing elective PCI and are able to give informed consent are eligible for study.
    Exclusion Criteria:

    • The end-stage renal failure

    • The patients who are relieving dialysis

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Xijing Hospital Xi'an Shaanxi China 710032

    Sponsors and Collaborators

    • Xijing Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Xijing Hospital
    ClinicalTrials.gov Identifier:
    NCT01372891
    Other Study ID Numbers:
    • xjyy110502
    First Posted:
    Jun 14, 2011
    Last Update Posted:
    Nov 22, 2011
    Last Verified:
    Nov 1, 2011
    Keywords provided by Xijing Hospital
    Contrast Induced Nephropathy
    percutaneous coronary interventions
    Additional relevant MeSH terms:
    Kidney Diseases
    Myocardial Ischemia
    Ischemia

    Study Results

    No Results Posted as of Nov 22, 2011